"Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies. Currently there 40 transdermal patches available in the market and more than 70 patches are in clinical pipeline.
Transdermal patches have made their place in global market in past few decades as an alternative to conventional therapeutic for various disease indications. Systemic drug delivery could be achieved by oral and prenatal methods but they have several limitations due to which many patients often find them inconvenient. Pharmaceutical companies have identified these problems as an opportunity to develop transdermal patches for generating significant revenues. This problem was identified early and advancements in biotechnology helped in the introduction of transdermal patches in global market. Nowadays, they are available for different disease indications and generally found suitable for large number of people having different disease indications. As a result, numbers of users are escalating at tremendous rates which are steadily increasing the global size.
Transdermal patches are widely accepted among physicians and patients due to their non-invasive, pain free and easy administration. In recent years, the growth of transdermal patch market has increased and expected to increase significantly in coming years. Higher investments in research and development could be attributed to the success of transdermal patch market. Number of disease indication treated by them is increasing steadily leading to higher market penetration. Every year various transdermal patches are introduced in globally leading to increased market size.
Transdermal patches presently donning the market are formulated in accordance with requirement of the medicinal therapy. They can be worn for as low as 8 hours to as long as 7 days depending on the therapeutic indication. These patches are secured with adhesives, which are designed to adhere comfortably to the skin which in turn allows a patient to use the patches for as long as is indicated by his or her physician. Transdermal drug delivery provides excellent control of the rate of delivery directly into the bloodstream. It also offers a predictable pharmacokinetic profile and constant drug levels over extended periods of time without the extreme peak/trough fluctuations inherent in oral administration with the inherent power of discontinuation of therapy immediately by simply removing the patch.
Strong clinical pipeline could be observed in case of transdermal patches which reflect the interest of pharmaceutical companies in this segment. Before marketing approval they have to undergo strict testing and checking for various qualitative parameters. They must be stable, chemically unreactive, hypo allergic, nontoxic and easy to manufacture. High throughput methods are expected to increase the suitable polymer screening rates along with reduced time consumption. Bioequivalence of therapeutic in transdermal patch with same drug administrated via different route have known efficacy must be shown. Similarly, independent of patch type they must show bioequivalence in clinical trials before getting marketing approval from medical regulatory authorities. Various products are at different stages of clinical trials which will be introduced in global market in coming years.
"Global Transdermal Patch Market & Clinical Pipeline Outlook 2022" report highlights:
- Introduction & Classification of Transdermal Patch
- Mechanism of Transdermal Patch Drug Delivery
- Transdermal Patch v/s Traditional Drug Delivery Methods
- Global Transdermal Patch Clinical Pipeline Overview
- Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase
- Global Transdermal Patch Market Future Prospects
Table of Contents
1. Introduction to Transdermal Patch
2. Classification of Transdermal Patches
- 2.1 Single/ Multiple-Layer Drug-in-Adhesive
- 2.2 Reservoir Transdermal Patches
- 2.3 Matrix Based Transdermal Patches
- 2.4 Vapor Patch
- 2.5 Active and Passive Patch
3. Why There Exist Need for Transdermal Patches?
4. Mechanism of Transdermal Patch Drug Delivery
- 4.1 Properties of Transdermal Therapeutics
- 4.2 Components of Transdermal Patch
- 4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal Patch
5. Transdermal Patch v/s Traditional Drug Delivery Methods
6. Global Transdermal Patch Market Outlook
- 6.1 Global Market Scenario
- 6.2 Regional Trends
7. Global Transdermal Patch Clinical Pipeline Overview
- 7.1 By Phase
- 7.2 By Region/Country
- 7.3 By Drug Class/Molecule
- 7.4 By Company
- 7.5 By Orphan & Fast Track Status
- 7.6 By Mode of Action
8. Global Transdermal Patch Market Dynamics
- 8.1 Favorable Market Parameters
- 8.2 Commercialization Challenges
9. Global Transdermal Patch Market Future Prospects
10. Global Transdermal Patch Clinical Insight
- 10.1 Unknown
- 10.2 Research
- 10.3 Preclinical
- 10.4 Clinical
- 10.5 Phase-I
- 10.6 Phase-I/II
- 10.7 Phase-II
- 10.8 Phase-II/III
- 10.9 Phase-III
- 10.10 Preregistration
- 10.11 Registered
11. Marketed Transdermal Patch Clinical Insight by Company, Indication & Phase
12. Competitive Landscape
- 12.1 3M Pharmaceuticals
- 12.2 Acrux
- 12.3 Agile Therapeutics
- 12.4 Allergan
- 12.5 ANI Pharmaceuticals
- 12.6 Antares Pharma
- 12.7 Bayer HealthCare Pharmaceuticals
- 12.8 Corium International
- 12.9 Chase Pharmaceuticals
- 12.10 DURECT Corporation
- 12.11 Endo Pharmaceuticals
- 12.12 Fempharm
- 12.13 Hisamitsu Pharmaceutical
- 12.14 Immune Pharmaceuticals
- 12.15 Imprimis Pharmaceuticals
- 12.16 Ipsen Bioscience
- 12.17 Johnson & Johnson
- 12.18 LaSalle Laboratories
- 12.19 Lavipharm-increase
- 12.20 MINRAD International
- 12.21 NeurogesX
- 12.22 Noven Pharmaceuticals
- 12.23 NuPathe
- 12.24 Nuvo Research
- 12.25 Novartis
- 12.26 Pain Therapeutics
- 12.27 ProStrakan
- 12.28 Purdue Pharma
- 12.29 Sanofi
- 12.30 Scilex Pharmaceuticals
- 12.31 Senju Pharmaceutical
- 12.32 Somerset Pharmaceuticals
- 12.33 Teikoku Seiyaku
- 12.34 Therapeutic Discovery Corporation
- 12.35 Transdermal Delivery Solutions Corp
- 12.36 UCB-full form
- 12.37 Xel Pharmaceuticals
- 12.38 Zosano Pharma
List of Figures
- Figure 1-1: Steps Involved in Transdermal Permeation
- Figure 1-2: Ideal Properties of Transdermal Patch
- Figure 2-1: Types of Commercially Available Transdermal Patch
- Figure 4-1: Properties of Transdermal Therapeutics
- Figure 4-2: Components of Transdermal Patch
- Figure 4-3: Types of Permeation Enhancers
- Figure 4-4: Schematic Representation of Iontophoresis
- Figure 4-5: Mechanism of Scopolamine Transdermal Patch
- Figure 4-6: Mechanism of Nicotine Transdermal Patch
- Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
- Figure 5-1: Issues with Traditional Drug Delivery Methods
- Figure 5-2: Advantages of Transdermal Patch
- Figure 5-3: Consistent Drug Supply by Transdermal Patch
- Figure 6-1: Global - Transdermal Patch Market Opportunity (US$ Billion), 2016-2022
- Figure 7-1: Global - Transdermal Patch Pipeline by Phase (%), 2017 till 2022
- Figure 7-2: Global - Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
- Figure 7-3: Global - Transdermal Patch Pipeline by Phase (%), 2017 till 2022
- Figure 7-4: Global - Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
- Figure 7-5: Global - Transdermal Patch Pipeline by Region (%), 2017 till 2022
- Figure 7-6: Global - Transdermal Patch Pipeline by Country (%), 2017 till 2022
- Figure 7-7: Global - Transdermal Patch Pipeline by Drug Class/Molecule (%), 2017 till 2022
- Figure 7-8: Global - Transdermal Patch Pipeline by Company (%), 2017 till 2022
- Figure 7-9: Global - Transdermal Patch Pipeline by Ophan & Fast Track Status (%), 2017 till 2022
- Figure 7-10: Global - Transdermal Patch Pipeline by Mode of Action (%), 2017 till 2022
- Figure 8-1: Drivers for Transdermal Patch
- Figure 8-2: Transdermal Patch Market Commercialization Challenges
- Figure 12-1: Acrux Clinical Pipeline
- Figure 12-2: Agile Therapeutics Clinical Pipeline
- Figure 12-3: Antares Pharma Clinical Pipeline
- Figure 12-4: Corium International Clinical Pipeline
- Figure 12-5: Durect Corporation Clinical Pipeline
- Figure 12-6: Endo Pharmaceuticals Clinical Pipeline
- Figure 12-7: Immune Pharmaceuticals Clinical Pipeline
- Figure 12-8: Novartis Clinical Pipeline
- Figure 12-9: Senju Pharmaceuticals Clinical Pipeline
- Figure 12-10: Xel Pharamaceuticals Clinical Pipeline
- Figure 12-11: Zosano Pharma Clinical Pipeline
List of Tables
- Table 2-1: Differences between Active & Passive Transdermal Patches
- Table 4-1: Transdermal Patches for Various Disease Indications
- Table 12-1: Pain Therapeutics Clinical Pipeline
